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a  b s t r  a c  t
Activated  synovial macrophages  play  a key  role in  Rheumatoid  Arthritis  (RA).  Recent  studies  have
shown  that  folate  receptor beta  (FRb)  is specifically expressed  by activated  macrophages.  Therefore
a  folate-based  nanodevice  would provide the  possibility of delivering  therapeutic agents  to  activated
macrophages  without  affecting  normal  cells and tissues.
This  study  shows  for the  first  time  the  sonochemical  preparation  of HSA  nanocapsules  avoiding toxic
cross  linking  chemicals  and emulsifiers  used in other methods.
Production  of HSA  nanocapsules  was optimized  leading  to  a  diameter  of 443.5 ± 9.0  nm  and  a  narrow
size distribution  indicated by a  polydispersity index  (PDI)  of 0.066  ±  0.080. Nanocapsules  were  surface
modified  with  folic acid  (FA)  and the  FA  content was determined to be 0.38 and 6.42  molecules FA  per
molecule  HSA,  depending on the surplus of FA employed.  Dynamic  light  scattering was  used to determine
size,  PDI  and  zetapotential  of the  produced nanocapsules  before  and after  surface  modification.  FA distri-
bution  on the  surface of HSA  nanocapsules  was  localized  three-dimensionally  after  fluorescence  labeling
using confocal  laser  scanning microscopy (CLSM). Furthermore,  specific  binding and  internalization  of
HSA  nanocapsules  by FRb-positive  and FRb-negative  macrophages,  obtained  from  human  peripheral
blood  mononuclear cells, was demonstrated by flow cytometry.  FRb-expressing  macrophages  showed
an  increased binding for  FA-modified  capsules  compared  with  those  without  FA.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune
disorder that is characterized by inflammation of  the joints. Chron-
ically activated synovial macrophages play a key role in this
inflammatory disease with numbers and level of macrophage acti-
vation correlating with the extent of joint inflammation and tissue
degradation (Adamopoulos et al., 2006; Schett, 2008). Amongst
others, some therapies are  designed to eliminate the entire popu-
lation of  macrophages. However, this can cause severe side effects
since macrophages have an essential function in fighting infectious
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diseases and promoting tissue repair. Consequently, specific elimi-
nation of the sub-population of chronic activated macrophages has
been  suggested as an alternative to the elimination of  the entire
macrophage population. Delivery of  therapeutic agents selectively
to pro-inflammatory cells would avoid toxicity and collateral dam-
age to healthy cells. Recent studies have shown that the folate
receptor beta (FRb),  which displays a high affinity for FA,  is specif-
ically expressed by activated macrophages (Puig-Kröger et  al.,
2009; Ross et  al., 1999; Van Der Heijden et  al.,  2009). Therefore
a folate-based nanodevice would provide the possibility of  deliver-
ing therapeutic agents to activated macrophages without affecting
normal cells and tissues.
Various types of folate conjugated drug delivery systems, such
as liposomes (Gabizon et al., 1999), copolymer nanoparticles (Stella
et al., 2000),  baculovirus (Kim et al., 2007)  and nanoparticles pro-
duced by  HSA (Ulbrich et al., 2011)  were  previously described. Due
to their uniquely diverse structures and functions, proteins are
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described to  be highly interesting for the creation of new materials
(Witus and Francis, 2011). HSA shows various valuable properties
such as biodegradability, biocompatibility, effective drug loading
capacity due to drug-binding properties of  natural albumin and
water solubility (Müller et al., 1996). HSA provides several func-
tional groups on the surface which can  be easily used for surface
modification. Based on coupling to these functional groups, FA
could be specifically attached onto the surface of the nanode-
vice rendering it recognizable by activated macrophages. However,
many conventional techniques for the preparation of  protein based
nanocapsules involve cross-linking with toxic chemicals (Langer
et al., 2003). Here we describe a strategy for the preparation of HSA
nanocapsules which avoids toxic cross-linking chemicals such as
glutaraldehyde commonly used in the desolvation.
Sonochemical methods have previously been  described for the
preparation of protein microspheres with an average diameter of
2.5 mm (Grinstaff and Suslick, 1991; Silva et al., 2011). However,
it was reported that  small nanoparticles were taken up more effi-
ciently by the cells, when compared to such  microparticles (Suri
et al., 2007; Panyam and Labhasetwar, 2003). Likewise, in vivo
experiments demonstrated that nanoparticles show a better per-
formance since they diffused throughout the sub-mucosal layers
while microparticles were predominantly localized in  the epithe-
lial lining (Desai et al., 1996).  Consequently, in  this study, stable
FA-functionalized HSA nanocapsules in a  size range of 500 nm
were developed. The absence of  crosslinking chemicals and emul-
sifiers in the production of  these nanocapsules also provides an
advantage from the economical point of  view. Confocal laser scan-
ning microscopy (CLSM) has the advantage over conventional light
microscopy and scanning electron microscopy of gaining infor-
mation about the three dimensional localization of fluorescence
labeled compounds (Lamprecht et al., 2000). Thus, we used CLSM
to monitor the reaction conditions and allow three-dimensional
analysis of FA distribution on the surface of HSA capsules after
fluorescence labeling of FA and HSA. Furthermore, specific internal-
ization of FA modified nanocapsules was shown in primary human
macrophages.
2. Materials and methods
2.1. Materials
Human serum albumin (HSA), folic acid (FA), N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride
(EDAC), N-hydroxysuccinimide (NHS), n-dodecane, dimethyl-
formamide (DMF), fluorescein 5(6)-isothiocyanate (FITC) and
fluorescent red mega 520 NHS ester (fluorescent red) were
purchased from Sigma–Aldrich (Steinheim, Germany). All other
reagents were used in analytical grade.
2.2. Methods
2.2.1. Fluorescent labeling
For CLSM studies FA and HSA were labeled with fluorescent
dyes prior to capsule production. FA was labeled with fluorescent
red. Therefore, 1 mg  of FA was dissolved in 200  mL buffer (50 mM
bicarbonate buffer, pH  9) and 150  mL of DMF  were added. 1 mg  of
fluorescent red was dissolved in  50 mL DMF. 14 mL of  fluorescence
red stock solution (1 equiv.) were mixed with 70 mL of  FA stock
solution (1 equiv.). 100 mL  of  DMF  were added and the mixture was
shaken for 12  h at 25 ◦C. The mixture was purified by  SEC using
a HiTrap Desalting column (GE  Healthcare Europe GmbH, Vienna,
Austria) installed on an  Äkta Purifier system (Amersham Pharma-
cia Biotech, Uppsala, Sweden), with 50 mM potassium phosphate
and 100 mM NaCl (pH 7) as eluent, at the flow rate of 1 mL min−1 to
Table 1
Reaction conditions for  the preparation of HSA nanocapsules by ultrasonication.
Sample Treatment time [min] Amplitude control [%]  Pulsation [%]
1 5 50 10
2 5 50 50
3 5 70 10
4  5 70 50
5 10 50 10
6  10 50 50
7  10 70 10
8  10 70 50
9 10 60 20
remove unlinked FA. Fractions which showed absorbance at 520 nm
for fluorescent red and 368 nm for FA,  respectively were collected.
For labeling with FITC, 4 mL  of a  HSA solution (10 mg mL−1 in
bicarbonate buffer, pH  9.2) were mixed with 200 mL  of  FITC solu-
tion (5 mg  mL−1 in  DMSO). This mixture was shaken for 4 h at
25 ◦C under light protection. Thereafter the mixture was  purified by
SEC using a  HiPrep 26/10 Desalting column (GE Healthcare Europe
GmbH, Vienna, Austria) using the same settings like described
above at a flow  rate of 3 mL  min−1 to remove excess FITC. Fractions
showing absorbance at 280  and 485 nm were collected and reduced
to a  volume of 4 mL using a Vivaspin 30  kD centrifugal separa-
tor at 5000 rpm using Biofuge primo (Heraeus, Buckinghamshire,
England).
2.2.2. Production of HSA nanocapsules
For nanocapsule production, a mixture of 50% FITC-labeled and
50% unlabeled HSA was  used.  10  mL HSA-solution (2 mg  mL−1 in
100 mM potassium phosphate buffer, pH  8) were combined with
6.6 mL of  dodecane. This mixture was  sonicated using a  13 mm
disrupter horn connected to Branson Sonifier 250 on ice using
the time, amplitude control and pulsation parameters as  specified
below (Table 1). Horn amplitudes are specified for certain ampli-
tude control settings (21.0 mm for an  amplitude control setting of
10%; 76.0 mm for 50%, 145.0 mm for 100%). A  power of  70 W was
required to maintain the amplitude for a given amplitude control
setting of 50%. For phase separation the samples were stored 4 ◦C for
12 h.  Thereafter, the organic phase was  removed and the nanocap-
sules were washed three times with 100 mM sodium-phosphate
buffer, pH  7.4 by  centrifuging (5 min, 5000 rpm) and pouring away
the supernatant. The solution was  filtered through a 0.8  mm syringe
filter to  remove bigger capsules.
2.2.3. Surface modification
Coupling of FA on HSA nanocapsules: FA  was coupled covalently
on the surface of HSA nanocapsules in different concentrations.
Stock solutions of FA, NHS and EDAC were prepared in  130 mM
NaHCO3 buffer (pH 7) as  follows, FA: 5  mg  mL−1,  NHS: 20 mg mL−1,
EDAC: 20 mg  mL−1. FA was  mixed with 50  equiv. of EDAC and NHS
and the mixture was  activated for 20 min  at 25 ◦C. Thereafter, the
HSA nanocapsule solution was combined with different concen-
trations of activated FA (10 equiv., 50  equiv. to HSA concentration)
and reacted for 12  h at room temperature. Subsequently, the cap-
sules were separated from uncoupled FA  by  washing five times with
ddH2O using Vivaspin 30 kD  at 5000 rpm.
2.2.4. Analysis
FA  and HSA concentration:  The concentration of  FA in free conju-
gates was determined photometrically. A  calibration curve of FA
samples with concentrations from 1 to 500 mg mL−1 in 130 mM
NaHCO3 buffer (pH 7) was recorded at 368 nm.  The HSA con-
centration was determined using Roti®-Nanoquant (Carl Roth
GmbH +  Co. KG, Karlsruhe, Germany) which is based on the method
of Bradford (Bradford, 1976). For the determination of FA and HSA
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concentrations in capsules, samples were freeze dried and the dry
powder was re-dissolved in 130 mM NaHCO3 buffer (pH 7) to dis-
integrate capsules and give a solution of free HSA and HSA–FA
molecules. Disintegration of  capsules was followed by monitor-
ing the number mean of particles using DLS. The FA concentration
was determined by calculating the area of the absorbance peak at
368 nm and interpolation. For this purpose, a  calibration curve was
recorded with different concentrations of  FA in  the presence of HSA
nanocapsules as background.
The interference of HSA and FA on  the different analysis methods
was tested. Mixtures of  HSA and FA with known concentrations of
both analytes were prepared and the concentrations were deter-
mined with the described methods. Measured and theoretical
values were compared to confirm that FA and HSA have no influence
on the analysis methods.
Confocal laser scanning microscopy: Surface modified HSA-
capsules in  the micron range were used as model to perform
CLSM experiments with a Leica TCS SPE Confocal microscope
(Leica Microsystems GmbH, Mannheim, Germany). Laser light
wavelengths of 532 nm and 488 nm were used for the excita-
tion of fluorescent red and FITC, respectively. The  emitted light
was detected in the range of 644–684 nm for fluorescent red and
500–556 nm for FITC. For every channel and every field of view,
laser intensity, photomultiplier gain and offset were individually
modified to optimize the signal/noise ratio.  Confocal stacks were
acquired with an ACS APO 63.0× 1.30 oil objective by  applying a
Z-step of 6.01 mm.  Volume rendering and three dimensional mod-
els were created with the software Imaris7.0 (Bitplane, Zurich,
Switzerland).
Dynamic light scattering (DLS):  The mean size of HSA  nanocap-
sules was determined by DLS using  Zetasizer Nano ZS (Malvern
Instruments GmbH, Herrenberg, Germany). Measurements were
performed in  triplicates at 25 ◦C with angle detection at 173◦.
Nanocapsules were diluted with 100  mM  sodium-phosphate
buffer, pH 7.4–0.1 mg mL−1. Size distribution was  characterized by
the PDI. Zeta potential was  determined based on  a combination of
laser Doppler velocimetry and phase analysis light scattering using
Zetasizer Nano ZS.
2.2.5. Cell studies
Human peripheral blood mononuclear cells were isolated from
buffy coats of healthy volunteers from the Instituto Português do
Sangue (IPS, Porto, Portugal) by centrifugation over Lymphoprep
(Axis-Shield) and monocytes were further purified by magnetic
cell sorting using CD14 microbeads (Miltenyi Biotec). Monocyte-
derived macrophages were generated in RPMI 1640 (supplemented
with 10% FCS, 100 U mL−1 penicillin and 100  mg  mL−1 strepto-
mycin) in the presence of 50  ng  mL−1 M-CSF (Pepro Tech) for 7 days
followed by an activation of 24  h with 20  ng mL−1 IL-4 (Pepro Tech).
The presence of surface FRb  in  macrophages was evaluated
by flow cytometry using a  monoclonal FRb antibody (Exbio,
Prague, Czech Republic). Prior to antibody staining, Fc receptors
were blocked with FcR Blocking Reagent (Miltenyi Biotec). An
isotype-matched monoclonal antibody was used as negative con-
trol. Flow cytometry analysis was performed with a FACSCalibur
flow cytometer (BD Biosciences) and data was analyzed using
FlowJo software version 8.7 (Tree Star Inc.).
To  obtain FRb-positive and FRb-negative macrophages, mono-
cytes were incubated with 10 ng mL−1 GM-CSF (Pepro Tech) for 7
days. FRb-positive and FRb-negative macrophages were then sep-
arated using a FACSaria cell  sorter (BD Biosciences).
Binding and internalization of  HSA nanocapsules by
macrophages was assessed by flow cytometry while all tests
were performed in  duplicates. Briefly, macrophages were incu-
bated for 1.5 h  with 0.1 mg  mL−1 HSA nanocapsules in  complete
RPMI at 37 ◦C  (binding and internalization allowed) or at 4 ◦C
(binding only). After incubation cells  were washed with PBS (pH
7.4) or with acidic NaCl 0.9% (pH  3). Data was acquired on a
FACScalibur flow  cytometer. The binding was determined as  the
geometrical mean fluorescence intensity of  the HSA  nanocapsules
corrected for the background staining of  cells not incubated with
the nanocapsules. Mean fluorescence intensity equal or below 1.0
means no binding.
The viability of  macrophages in the presence of the HSA
nanocapsules was  evaluated using the Resazurin assay.  This
method is based on the ability of  living cells to convert
the dye Resazurin into a fluorescent product (Resorufin). M-
CSF-differentiated macrophages were incubated with different
concentrations of HSA-nanocapsules for 24 h at 37 ◦C, followed by
incubation with Resazurin for  4 h.  Fluorescence was then read  at
560/590 nm in  a  plate-reading fluorometer (SpectraMax Gemini XS,
Molecular Devices).
3. Results and discussion
3.1. Preparation of HSA nanocapsules
A  sonochemical method for the production of FA-functionalized
HSA nanocapsules was developed. The strategy presented here
avoided the use of  toxic chemicals for cross-linking and aimed at a
narrow size distribution to allow delivery of therapeutic agents to
activated macrophages without affecting normal cells and tissues.
A  commonly used method for the preparation of  albumin
nanoparticles is the desolvation technique (Langer et al., 2003).
Using this method, nanoparticles in a  size range between 150  and
280 nm can be prepared. A  disadvantage of  this method is  the use
of toxic glutaraldehyde as crosslinker to stabilize the prepared
nanoparticles. The use of  toxic cross-linkers for the preparation
of  protein aqueous microspheres can be avoided by using sono-
chemical strategies. However, previously capsules in a size range
of 2.5 mm were achieved (Grinstaff and Suslick, 1992), which is far
too big in  order to  allow for specific cell internalization. Particles
in this size  range are recognized by macrophages as foreign parti-
cles and are consequently taken up through phagocytosis (Ahsan
et al., 2002). This would not only lead to elimination of  the particles
before showing a therapeutic effect, but would also affect healthy
macrophages. In non-phagocytic cells nanoparticles with a  size of
100 nm showed a  relatively higher  intracellular uptake compared
to  microparticles (Suri et  al.,  2007; Panyam and Labhasetwar, 2003).
Therefore, a specific non-phagocytic uptake due to recognition of
folic acid by the FRb  can only be achieved with nanoparticles. Size is
also  an important factor for in vivo experiments since it  was shown
that 100 nm particles diffused throughout the sub-mucosal layers
while microparticles were predominantly localized in the epithelial
lining (Desai et al.,  1996).
In this study, optimization of  energetic and time parameters
in  ultrasound-based formation of  nanocapsules lead to an  aver-
age diameter of  below 500 nm and a narrow size distribution. Nine
combinations of amplitude, pulsation and total treatment time
were tested while the pH value was fixed to pH  8,  which was pre-
viously demonstrated to be the optimum for protein nanoparticle
production (Sebak et  al., 2010).
DLS measurements of  HSA-capsules after several washing steps
showed a broad size distribution indicated by a  PDI  value around
0.3 in all samples. Data analysis proved that two  populations
of  particles with diameters around 300 nm and around 900 nm,
respectively, were obtained. Consequently, a  filtration step was
incorporated to eliminate the larger diameter particle population.
Testing filter pore sizes of 1.0 mm and 0.8 mm, with the smaller
pore size particles larger than 800 nm were successfully eliminated.
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Fig. 1. Parameter (pulsation, amplitude control, treatment time) optimization of  ultrasonic production of HSA nanocapsules towards small diameters and PDI  (polydispersity
index).  Diameter and PDI were measured after filtration (pore size 1.0  and 0.8  mm).
Moreover, a  narrow size distribution with minimum PDI values of
around 0.07 was obtained.
Thus, in all subsequent experiments an amplitude control of
50%, pulsation 10% and 10 min  treatment time for sonication were
used. These optimized energetic and time parameters gave small
nanocapsules with a diameter of 443.5 ± 9.0 nm and a narrow size
distribution indicated by a PDI of 0.066 ±  0.080 (Fig. 1).
3.2. Surface modification
For recognition by activated macrophages, FA  was attached
to the surface of the nanocapsules via the carboxylic end of
the molecule, since the pteridine residue is responsible for FRb
recognition and therefore cannot be modified. The water soluble,
heterobifunctional cross-linker EDAC was used to activate FA-
carboxylic groups which further react with primary amines located
on the capsule surface.
Preliminary results indicated that  disintegration of nanocap-
sules was necessary prior to spectroscopic quantification of  FA at
368 nm and HSA quantification based on  a modified Bradford assay.
To exclude any interference of  HSA and FA absorption, calibra-
tion curves for FA quantification at 368 nm were recorded in the
presence of disintegrated HSA-nanocapsules as  background. Disin-
tegration of nanocapsules was  successfully demonstrated by using
DLS analysis showing a lower number mean of 73.39  ± 30.98 nm
and a PDI of 0.475 ± 0.186.
Capsules with two different concentrations of FA were pro-
duced to  compare the cell internalization ability as a function of
FA amount linked on the surface. The FA content on capsules was
determined to be 0.38 and 6.42 molecules FA per molecule HSA
respectively (Table 2). A maximum coupling yield of around 12.8%
Table 2
Concentration of  FA on nanocapsules calculated as molar ratio of  FA  molecules per
HSA  molecules used for the coupling reaction vs. FA concentration determined after
coupling reaction.
Amount FA per  HSA [mol mol−1] FA linked on HSA  [mol mol−1]
10 0.38 ± 0.02
50 6.42 ± 0.18
was  achieved when a  50 fold molar excess of  FA was used for the
coupling experiment.
3.2.1. Zetapotential, size, PDI
Size and PDI measurements showed that filtration is the essen-
tial step to obtain nanocapsules with a  narrow size distribution.
After filtration only nanocapsules with a diameter of around
500 nm and a PDI of 0.2 (Fig. 2)  were found. An increase in poly-
dispersity could be observed with higher amounts of FA linked
on the capsule surface. This effect can be correlated with results
from CLSM analysis where some inhomogeneity regarding cap-
sule modification was  seen. The zetapotential of the nanocapsules
was  around −20  mV  and only  a slight deviation could be observed
after FA  modification. With CLSM analysis it was verified that no
aggregate formation occurred, even though it  has been previously
described that a  zetapotential above (±)30 mV  was the balance
point between stable and  unstable suspensions (Mohanraj and
Chen, 2006).
Fig. 2. Diameter [nm], PDI and zetapotential [mV] of HSA  nanocapsules before and
after filtration (pore size 0.8 mm) and after surface modification with FA in different
molar excess (a) 0.38  mol  FA per mol  HSA and  (b) 6.42 mol FA per mol  HSA, both
filtered.
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Fig. 3. CLSM image (a) and 3D  reconstruction (b–d)  of  FITC-labeled HSA nanocapsules carrying fluorescent red labeled FA on the capsule surface. Blue: HSA, green: FA. (For
interpretation of the references to color  in this figure legend, the reader is referred to the  web version of the  article.)
Fig. 4. (Left) Binding/internalization of FITC-conjugated HSA nanocapsules FA (a) 0.38 FA per HSA [mol mol−1],  FA (b) 6.42 FA  per HSA [mol mol−1]  by  macrophages after
1.5  h  incubation at 37 ◦C or 4 ◦C followed by neutral or acidic washing. The  binding was determined by  flow  cytometry as the geometrical mean fluorescence intensity of the
HSA  nanocapsules. Mean fluorescence intensity equal or below 1.0 means no binding. (Right) FRb expression (flow cytometry analysis) in human activated macrophages.
Macrophages were obtained by  incubation with 50 ng mL−1 M-CSF for 7 days followed by  1  day of  activation with 20  ng mL−1 IL-4. Solid black line represents FRb expression
and  filled histogram represents the isotype control.
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3.2.2. CLSM characterization
Amongst other methods, CLSM was  used for the characteriza-
tion of surface modified HSA capsules. This method is a powerful,
nondestructive visualization technique for the characterization and
visualization of  structures on  the surface and inside of  particles
(Lamprecht et al.,  2000). Therefore, HSA capsules in  micron range
were prepared as a  model for nanocapsules. HSA and FA were
labeled prior to capsule production with the fluorescent dyes FITC
and fluorescent mega red 520  NHS-ester, respectively.
No aggregate formation occurred between capsules, single cap-
sules in micron range were clearly visible (Fig. 3). Using this method
we observed that within the same batch some single capsules were
completely modified with FA while others did not show any FA
derived fluorescence signal (Fig. 3). Albert et  al. (1952) had already
described in 1952 that pteridines have the ability to form strong
intermolecular hydrogen bonds through amino- and hydroxyl sub-
stituents and the heterocyclenitrogens. Due to  the fact that FA
contains the structural element of  pteridine this phenomenon
could be explained by  the strong intermolecular attraction of FA
molecules.
The three dimensional reconstruction of  a single capsule
showed a  shell of HSA that is  surrounding a cavity into which drugs
could be loaded. FA is clearly located on  the surface of the HSA cap-
sule. In  the reconstruction image FA is not completely surrounding
the capsule. This is  most likely an artifact due to signal loss of  fluo-
rescent red by  high laser energy input during the scanning process
(“photo bleaching” effect).
3.3. Cell studies
Previous studies have shown that macrophage activation plays
a significant role in the pathogenesis of RA (Schett, 2008; Xia et al.,
2009). The expression of FRb by activated macrophages in  the
inflamed sites of RA (Turk et al.,  2002; Van Der Heijden et  al., 2009;
Nakashima-Matsushita et  al., 1999), allows the use of this recep-
tor as a target for the specific delivery of  therapeutic agents. In
the present study, we evaluated the binding and internalization of
FA–HSA nanocapsules (a potential folate-conjugated drug delivery
system) by human FRb-expressing macrophages using flow  cytom-
etry. FRb-expressing macrophages (Fig. 4)  showed an increased
binding for capsules with FA when compared with those without
FA (Fig. 4). Moreover, the observed binding recedes when incuba-
tion occurs at 4 ◦C when the internalization is  not allowed (Fig. 4),
suggesting that capsules are being internalized by macrophages.
This conclusion is supported by the results observed after the acidic
vs. neutral wash of macrophages incubated with capsules. Since
the acidic wash eliminates any surface-bound capsules while the
neutral wash only  washes away unbound capsules, and no differ-
ence in the mean fluorescence intensity was observed between
the two conditions (Fig. 4), we conclude that the observed fluo-
rescence is due to internalized capsules. No significant difference
was observed between nanocapsules with 0.38 and 6.42 molecules
FA per molecule HSA, when nanocapsules with different amounts
of FA linked on the capsule surface were compared. This suggests
that a  maximum of 0.38 molecules FA per HSA  molecule is sufficient
for efficient FA–HSA targeting of macrophages.
The specificity of  FA–HSA nanocapsules for FRb-expressing
macrophages was further evaluated by incubating FRb-positive
and  FRb-negative macrophages with FA–HSA nanocapsules con-
taining 0.38 molecules FA  per molecule HSA. The internalization
of the FA-nanocapsules was higher in  FRb-positive macrophages
(mean fluorescence intensity of 2.58 ±  0.68) than in  macrophages
not expressing FRb  (mean fluorescence intensity of 1.67 ± 0.15),
indicating that  the binding/internalization of  capsules is mediated
through folate receptors. It has been reported that the reduced
folate carrier, another protein used for folate transport in cells,
Fig. 5. Viability of  macrophages in the presence of different concentrations of
HSA nanocapsules after incubation time of 24 h. Viability was analyzed using the
resazurin assay and  it is expressed as Relative Fluorescent Units.
does not transport folate conjugates (Paulos et al., 2004) such  as
the capusles developed in  this study, therefore the internalization
of FA–HSA nanocapsules must be mediated through FRb.
The viability of  macrophages in the presence of nanocapsules
was  also evaluated. The incubation of  macrophages with FA-
modified HSA nanocapsules reduced viability in a concentration-
dependent manner (Fig. 5). No toxicity was observed for HSA
capsules (Fig. 5),  as  these are  not internalized by macrophages
(Fig. 4).
4. Conclusion
This work demonstrates the production of stable, uniform (size)
HSA nanocapsules avoiding toxic crosslinking agents and emul-
sifiers. HSA nanocapsules in a size  range of 440 nm were surface
modified using different amounts of FA to  allow for specific cell
internalization by FRb  positive macrophages. Size, PDI  and zetapo-
tential were determined before and after surface modification.
Using CLSM analysis it  was  found that FA modification is not
uniform due to  strong intermolecular attraction of FA molecules.
Furthermore specific binding and internalization of FA modified
HSA-nanocapsules by FRb-positive macrophages was  achieved
in comparison with  non-modified nanocapsules. In addition, the
internalization of the FA-modified nanocapsules was three-fold
higher in FRb-positive macrophages than in  macrophages not
expressing FRb, showing that the binding/internalization of cap-
sules is being mediated through folate receptors. Further studies
should include an  internalization evaluation using other cell types
to confirm specificity, as  well as surface modification with other
target molecules to enhance specificity of macrophage internaliza-
tion. The folate based nanodevice produced during this study could
be used to deliver therapeutic agents to activated macrophages
without affecting normal cells and tissues. Consequently, future
investigation should focus on loading the nanodevices with differ-
ent drugs suitable for the treatment of  RA.
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